Unicycive’s crucial kidney medication trial achieves its primary objective
By publishing key bioequivalence results on a prospect created to increase adherence to treatment regimens for kidney illness, Unicycive Therapeutics has paved the way for entering a space pursued by Sanofi and Takeda.